2-cyano-benzenesulfonic acid | 500878-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-cyano-benzenesulfonic acid
• 英文别名: 2-Cyan-benzolsulfonsaeure；o-Cyan-benzol-sulfonsaeure；2-Cyanobenzenesulfonic acid
• CAS: 500878-49-9
• 化学式: C₇H₅NO₃S
• 分子量: 183.188
• InChiKey: XXKZYJFUOPNRCL-UHFFFAOYSA-N

物化性质

• 熔点：
  275-277 °C
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  五氯化磷 、 2-cyano-benzenesulfonic acid 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  List; Stein, Chemische Berichte, 1898, vol. 31, p. 1663

  摘要：

  DOI：
• 作为产物：
  描述：

  糖精 在 五氯化磷 作用下， 生成 2-cyano-benzenesulfonic acid
  参考文献：
  名称：

  Jesurun, Chemische Berichte, 1893, vol. 26, p. 2292

  摘要：

  DOI：

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• [EN] PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS<br/>[FR] COMPOSES DE PYRROLE ET PYRAZOLE PRESENTANT UN EFFET POTENTIATEUR SUR LES RECEPTEURS DU GLUTAMATE
  申请人：LILLY CO ELI

  公开号：WO2005040110A1

  公开（公告）日：2005-05-06

  The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.

  本发明涉及式(I)的吡咯和吡唑化合物及其药用可接受的盐，并且进一步涉及它们在治疗精神分裂症、与精神分裂症相关的认知缺陷、阿尔茨海默病、阿尔茨海默型痴呆、轻度认知障碍或抑郁症方面的应用。这些化合物作为谷氨酸受体的增强剂，特别是AMPA和GluR家族。
• Theoretical investigation on the dispersion of graded-index polymer optical fibers
  作者：G. Yabre

  DOI：10.1109/50.848400

  日期：2000.6

  Various experiments on polymer optical fibers (POF's) suggest that they present a large transmission capacity, but this is not confirmed by the standard theory. In this paper we present a full dispersion model based on evaluating the frequency response of the fiber instead of the direct calculation of the pulse broadening from the moments of the impulse response. The mathematical formalism is firstly displayed and subsequently applied to the graded-index POF made with polymethylmethacrylate (PMMA). The simulation results show that the baseband bandwidth is indeed enhanced due to the strong differential mode attenuation (DMA).

  对聚合物光纤（POF）的各种实验表明，它们具有很大的传输容量，但这一点并未得到标准理论的确认。在本文中，我们提出了一种完整的色散模型，该模型基于评估光纤的频率响应，而不是直接从脉冲响应的矩计算脉冲展宽。首先展示数学形式，然后将其应用于用聚甲基丙烯酸甲酯（PMMA）制造的梯度折射率POF。仿真结果表明，由于强差模衰减（DMA），基带带宽确实得到了增强。
• [EN] NOVEL SULFONATE-BASED TRIMEBUTINE SALTS<br/>[FR] NOUVEAUX SELS DE TRIMÉBUTINE À BASE DE SULFONATE
  申请人：GICARE PHARMA INC

  公开号：WO2013134869A1

  公开（公告）日：2013-09-19

  The present description relates to compounds of Formula I (A+ X-), a diastereoisomer, an enantiomer, or a mixture thereof, pharmaceutical composition comprising same and uses thereof for gastrointestinal endoscopic and medical imaging applications, and for the treatment of visceral pain: Where R1 and R2 are as defined herein

  本描述涉及式I化合物（A+ X-），其对映异构体、对映体或其混合物，包含相同化合物的药物组合物以及用于胃肠内窥镜和医学成像应用，以及用于治疗内脏疼痛的用途：其中R1和R2如本文所定义。
• E-commerce patents and shifting balances in patent law
  作者：S.C. Durant、T.C. Chuang

  DOI：10.1109/35.852040

  日期：2000.7

  The rules with respect to the patentability of software and business method inventions have loosened over the last decade to allow a broader range of patentability. Many patents issuing today are in the e-commerce area, and there is often a close relationship between what is being patented and generation of wealth. Critics of the surge of e-commerce patents argue these patents may stifle development of e-commerce. The level of concern of critics may be unwarranted since the broader range of patentability that has occurred has been balanced somewhat against a narrower scope of protection occurring during the same time period as a result of more restrictive claim interpretation during enforcement of patents. This more restrictive claim interpretation has created an onus on patent owners to effectively draft and prosecute patents to obtain protection commensurate with the scope of the inventions.

  在过去的十年中，有关软件和商业方法发明专利性的规则有所松动，允许专利性的范围更加广泛。如今，许多专利都属于电子商务领域，而且专利内容与创造财富之间往往有着密切的关系。对电子商务专利激增的批评者认为，这些专利可能会扼杀电子商务的发展。批评者的担忧可能是多余的，因为在同一时期，由于在专利实施过程中对权利要求的解释更具限制性，专利的可专利性范围有所扩大，但保护范围却有所缩小。这种限制性更强的权利要求解释使得专利所有人有责任有效地起草和申请专利，以获得与发明范围相称的保护。